Catalent Biologics partners with Path Malaria Vaccine Initiative to accelerate malaria vaccines

Catalent Pharma Solutions, provider of advanced delivery technologies and development solutions for drugs has announced a collaboration with Path, a nonprofit organisation and player in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).

The agreement will have Catalent Biologics employ its proprietary GPEx cell line technology, coupled with an ambr workstation workstation, which mimics the characteristics of classical bioreactors at micro scale, to develop, optimise the process for expression, and manufacture antibodies under cGMP conditions at its state-of-the-art Madison, Wisconsin facility, for further investigation by MVI and its partners.

Mike Riley, vice president and general manager of Catalent Biologics said. “Catalent has significant experience partnering with companies for the successful development of antibodies for innovative applications. Path is a leader in the field, working with partners to pioneer vaccine development approaches that could ultimately contribute to malaria elimination efforts. We are excited to be able to apply our technology and expertise to advance this important program.”

Path's MVI is helping accelerate the development of malaria vaccines and to ensure access where they are needed most.

Catalent’s GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. To date, seven GPEx-based antibody and protein products are approved and marketed, and 34 therapeutic candidates are currently in the clinic across the world.